Trial · NCT02555683
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation | QAW039 150 mg | 0.97 | 95% Confidence Interval 0.78 to 1.20 | events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation | QAW039 450 mg | 0.77 | 95% Confidence Interval 0.62 to 0.97 | events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation | Placebo | 0.93 | 95% Confidence Interval 0.75 to 1.16 | events/year | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation | QAW039 150 mg | 0.75 | Standard Error 0.067 | units on scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation | QAW039 450 mg | 0.81 | Standard Error 0.067 | units on scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation | Placebo | 0.68 | Standard Error 0.067 | units on scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in High Eosinophils Subpopulation | QAW039 150 mg | -0.88 | Standard Error 0.069 | units on scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in High Eosinophils Subpopulation | QAW039 450 mg | -0.94 | Standard Error 0.069 | units on scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in High Eosinophils Subpopulation | Placebo | -0.76 | Standard Error 0.070 | units on scale | |
| Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation | QAW039 150 mg | 0.169 | Standard Error 0.0257 | Liter | |
| Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation | QAW039 450 mg | 0.153 | Standard Error 0.0255 | Liter | |
| Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation | Placebo | 0.103 | Standard Error 0.0260 | Liter | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population | QAW039 150 mg | 0.92 | 95% Confidence Interval 0.77 to 1.09 | events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population | QAW039 450 mg | 0.75 | 95% Confidence Interval 0.62 to 0.90 | events/year | |
| Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population | Placebo | 0.96 | 95% Confidence Interval 0.80 to 1.15 | events/year | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population | QAW039 150 mg | 0.68 | Standard Error 0.053 | units on scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population | QAW039 450 mg | 0.73 | Standard Error 0.054 | units on scale | |
| Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population | Placebo | 0.61 | Standard Error 0.054 | units on scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in Overall Population | QAW039 150 mg | -0.83 | Standard Error 0.055 | units on scale | |
| Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in Overall Population | QAW039 450 mg | -0.90 | Standard Error 0.056 | units on scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02555683/results